Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

Int Guideline Harmonization Grp

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Original languageEnglish
Pages (from-to)E29-E41
Number of pages13
JournalLANCET ONCOLOGY
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2019

Cite this

@article{5c668b712f1f47679f2a766455c6e3c9,
title = "Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium",
abstract = "Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.",
keywords = "CISPLATIN-INDUCED OTOTOXICITY, PLATINUM-INDUCED OTOTOXICITY, INDUCED HEARING-LOSS, TERM-FOLLOW-UP, CEREBROSPINAL-FLUID, BRAIN-TUMORS, SODIUM THIOSULFATE, PEDIATRIC-PATIENTS, SHUNT PLACEMENT, GRADING SCALES",
author = "{Int Guideline Harmonization Grp} and Eva Clemens and {van den Heuvel-Eibrink}, {Marry M.} and Mulder, {Renee L.} and Kremer, {Leontien C. M.} and Hudson, {Melissa M.} and Roderick Skinner and Constine, {Louis S.} and Bass, {Johnnie K.} and Kuehni, {Claudia E.} and Thorsten Langer and {van Dalen}, {Elvira C.} and Edith Bardi and Nicolas-Xavier Bonne and Brock, {Penelope R.} and Beth Brooks and Bruce Carleton and Eric Caron and Chang, {Kay W.} and Karen Johnston and Kristin Knight and Nathan, {Paul C.} and Etan Orgel and Prasad, {Pinki K.} and Jan Rottenberg and Katrin Scheinemann and {de Vries}, {Andrica C. H.} and Thomas Walwyn and Annette Weiss and Zehnhoff-Dinnesen, {Antoinette Am} and Cohn, {Richard J.} and Wendy Landier and Nina Kadan-Lottick and Gill Levitt and Alex Hoetink and John Mussman",
year = "2019",
month = "1",
doi = "10.1016/S1470-2045(18)30858-1",
language = "English",
volume = "20",
pages = "E29--E41",
journal = "LANCET ONCOLOGY",
issn = "1470-2045",
publisher = "Academic Press",
number = "1",

}

TY - JOUR

T1 - Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors

T2 - a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

AU - Int Guideline Harmonization Grp

AU - Clemens, Eva

AU - van den Heuvel-Eibrink, Marry M.

AU - Mulder, Renee L.

AU - Kremer, Leontien C. M.

AU - Hudson, Melissa M.

AU - Skinner, Roderick

AU - Constine, Louis S.

AU - Bass, Johnnie K.

AU - Kuehni, Claudia E.

AU - Langer, Thorsten

AU - van Dalen, Elvira C.

AU - Bardi, Edith

AU - Bonne, Nicolas-Xavier

AU - Brock, Penelope R.

AU - Brooks, Beth

AU - Carleton, Bruce

AU - Caron, Eric

AU - Chang, Kay W.

AU - Johnston, Karen

AU - Knight, Kristin

AU - Nathan, Paul C.

AU - Orgel, Etan

AU - Prasad, Pinki K.

AU - Rottenberg, Jan

AU - Scheinemann, Katrin

AU - de Vries, Andrica C. H.

AU - Walwyn, Thomas

AU - Weiss, Annette

AU - Zehnhoff-Dinnesen, Antoinette Am

AU - Cohn, Richard J.

AU - Landier, Wendy

AU - Kadan-Lottick, Nina

AU - Levitt, Gill

AU - Hoetink, Alex

AU - Mussman, John

PY - 2019/1

Y1 - 2019/1

N2 - Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

AB - Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

KW - CISPLATIN-INDUCED OTOTOXICITY

KW - PLATINUM-INDUCED OTOTOXICITY

KW - INDUCED HEARING-LOSS

KW - TERM-FOLLOW-UP

KW - CEREBROSPINAL-FLUID

KW - BRAIN-TUMORS

KW - SODIUM THIOSULFATE

KW - PEDIATRIC-PATIENTS

KW - SHUNT PLACEMENT

KW - GRADING SCALES

U2 - 10.1016/S1470-2045(18)30858-1

DO - 10.1016/S1470-2045(18)30858-1

M3 - Review article

VL - 20

SP - E29-E41

JO - LANCET ONCOLOGY

JF - LANCET ONCOLOGY

SN - 1470-2045

IS - 1

ER -